The Health Canada peptide warning, a public advisory issued November 6, 2026, reports bacteria in seized injectable products; a November 12 notice reports another finding. Contaminated injections can cause serious infections and hospitalization. In severe cases, they can cause sepsis, life-threatening organ damage from the body's response to infection. Health Canada adds that the risk of infection is higher in people with a compromised immune system. The advisories do not report confirmed infections in people.
Peptides are short chains of protein building blocks. If a familiar peptide name caught your eye, the next question is which product was tested. A name alone doesn't connect the alert to a medication prescribed for you.
What the Health Canada peptide warning found
As of November 12, 2026, the day this article was written, Health Canada's November 6 public advisory reports bacteria in unauthorized injectable peptides it seized and tested. Unauthorized means the products had not been assessed for sale by Canada's regulator.
The bacteria included Acinetobacter seifertii, Acinetobacter nosocomialis and Propionibacterium (Cutibacterium) acnes. Health Canada seized over 11,400 vials in total from a supplier and two Canadian online retailers. That is the number seized, not the number tested or found contaminated.
Its example product names include MOTS-C, NAD+, Tesamorelin and Tirzepatide. It does not identify which named product contained which bacterium.
A separate November 12 advisory reports Sphingomonas aquatilis/melonis, another bacterial finding, in an injectable product seized from an Ottawa retail store. BPC-157 appears on that advisory's affected-products list, but the notice does not identify which named product tested positive.
For someone considering BPC-157, that distinction matters. The finding concerns seized products, and the label alone cannot establish another container's contents or quality.
What bacteria in peptide vials means
Sterility means being free of living germs. Chemical purity describes a sample's chemical makeup. A purity result cannot replace testing for living bacteria.
There is another separate concern: endotoxins, bacterial material that can remain after the bacteria die. In a 2024 study in the Journal of Medical Internet Research, Ashraf and colleagues reported endotoxin in online semaglutide samples despite finding no living germs. Those samples were separate from the Canadian seizures.
The endotoxin guide explains that distinction. Confirming the ingredient, measuring its amount and checking for contamination answer different questions. A report needs to say which checks were performed and connect the results to the batch, the group prepared together.
What the prescription route changes
A prescription gives the medication a documented care relationship. There is an identifiable clinician, a dispensing pharmacy and records connecting the person to the preparation. Compounding means preparing a medicine for a particular prescription.
At Promise, a licensed provider reviews every request, and not everyone qualifies. BPC-157 and MOTS-c prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications. These formulations are not FDA-approved.
State pharmacy law governs the pharmacy's work. FDA explains that state boards generally have primary responsibility for day-to-day oversight of these pharmacies. Federal requirements also apply.
USP, the United States Pharmacopeia, publishes medicine-quality standards. Its Chapter <797> standards cover sterile preparation, staff skills, the work environment, records and testing requirements. State and federal regulators oversee pharmacies; USP writes the standards.
For a person prescribed MOTS-c, the practical difference is having a pharmacy that can investigate the preparation and its records. Its label and batch information give a complaint somewhere specific to go. That relationship cannot promise that a quality problem will never happen.
What the warning does not mean
Finding bacteria in a vial does not prove an infection occurred in a person. Neither Canadian advisory reports a linked patient infection or gives an injury count.
Sepsis is a possible consequence of infection, not a diagnosis made from a vial test alone. A clinician needs to assess the person. Health Canada's warning about that risk remains serious.
The seizure total also cannot tell us how common contamination is across online products. The November 6 notice does not give the total number tested. Dividing positive findings by 11,400 would use the wrong number.
Label accuracy is another question, explored in Australia's TB-500 testing report. Neither a label nor an ingredient measurement answers whether a vial is sterile.
Health Canada is Canada's regulator; the U.S. framework differs, including the HHS peptide compounding policy.
What this means for a tesamorelin prescription
Tesamorelin appears among the November 6 example names. That does not identify every preparation with that ingredient as an affected product. The useful connection is the product's source and batch, not the shared molecule name.
Tesamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA does not review compounded medicines for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
Prescribed products still carry risks. FDA warns that poor compounding practices can cause contamination or incorrect strength, leading to serious injury and death. The pharmacy relationship provides accountability, not a guarantee of perfect quality.
What to watch next
Useful follow-up would identify affected batches, the number of samples tested and any confirmed illnesses. Health Canada says it will continue seizures, testing and work to disrupt distribution. Those updates could clarify how far the findings reach.
The current instructions are direct: “Do not buy or use these products.” After use, redness, swelling, injection-site pain, fever, chills or feeling unwell may signal a serious infection. Health Canada's instruction is to “seek medical attention immediately.”
The agency also directs people to take remaining unauthorized products to a local pharmacy for proper disposal or follow local hazardous-waste guidance. It asks people to report side effects and product complaints.
For prescribed care, the clinician assesses symptoms and the dispensing pharmacy investigates the product. A label photo, batch number and account of what happened can help connect the concern to the right records.





